Takeda Ventures focuses on high-caliber therapeutic and platform based opportunities around the world.
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. We are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Apr 19, 2021
Adaptate Biotherapeutics
|
Series A | £13M | Biotechnology | — |
Nov 13, 2019
Avidity Biosciences
|
Series C | $100M | Biotechnology | — |
Oct 3, 2019
Arcellx
|
Series B | $85M | Biopharma | — |
Aug 8, 2018
Ambys Medicines
|
Series A | $60M | Biotechnology | Yes |